Anticoagulation FORUM

fresh insights

November 2018 Edition

Webinar: Evidence-Based Best Practices for Outpatient Management of Warfarin * AC Forum 2019: Early Bird Deadline * CDC Public Health Webinar * COVET Trial: Participants Needed * Andexanet Alpha Survey * CoaguChek Recall

Anticoagulation FORUM | Webinar Lunch & Learn

December Webinar: Evidence-Based Best Practices for Outpatient Management of Warfarin

Wednesday, December 5, 2018, 12:00 PM ET

Guest Speaker:
Adam Rose, MD, MSc, FRCPC

AC Forum Moderators:
Tracy Minichiello, MD; Michael Streiff, MD;
Sara Vazquez, PharmD; Diane Wirth, ANP, CACP

Many best practices have been described for organizing a clinic to manage warfarin. Although these practices may have face validity, they may not be based on empirical analysis. Here, we describe our decade-long effort to apply the Structure-Process-Outcome model of quality measurement as a basis for measuring and improving outpatient warfarin management in the Veterans Health Administration. The purpose of the article is to raise awareness of this body of work with pharmacists who could potentially incorporate the findings of this work into their own practice settings.

We conclude with concrete suggestions for immediate implementation in clinical settings.

Register Now!

Conference Deadlines Approaching

Join us **April 11-13, 2019 at The Diplomat Beach Resort in Ft. Lauderdale** for the most comprehensive anticoagulation conference. Hear industry leaders discuss current topics and provide practice changing, evidence-based information that can be brought back to the clinic for immediate implementation. Check out our **program** and **faculty** and reserve your spot today!

Early Bird Rates End December 1

Abstract Deadline December 15

Register Today

Submit Abstract

Hotel Information

The Diplomat Beach Resort brings iconic hospitality back, wrapped in a spirited escape-to-sunny-shores feeling.

Standard Room: $249/night*
Deluxe Room w/ Balcony: $279/night*

Book Now

**taxes and fees additional*

PUBLIC HEALTH WEBINAR SERIES ON BLOOD DISORDERS

BRINGING SCIENCE INTO PRACTICE

Scientific Update on Venous Thromboembolism Prophylaxis in Orthopedic Surgery: Making Sense of the Recommendations

Thursday, December 6, 2018 • 2:00–3:00 PM ET

Venous thromboembolism (VTE) is a common complication in patients undergoing orthopedic surgery, particularly total hip and knee arthroplasty. While the risk of VTE is highest during the first four weeks after surgery, the risk of VTE exceeds that for the general population for months after surgery. The extended risk period for VTE after orthopedic surgery has spurred clinical investigation of extended thromboprophylaxis, which led to its adoption in routine clinical care.

This free, one-hour webinar, hosted by AC Forum Board member Michael Streiff, MD, is presented by the Centers for Disease Control. Dr. Streiff will review the following:

- The epidemiology of VTE after orthopedic surgery
- Landmark studies of thromboprophylaxis
- Current recommendations for VTE prevention after orthopedic surgery
- An overview of current studies of VTE prophylaxis for orthopedic surgery
- Potential future directions in orthopedic thromboprophylaxis

REGISTER

For more information please contact **Cynthia Sayer** at **cay1@cdc.gov.**

COVET Trial: Opportunity to Participate

In the COVET (Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism) trial, we are testing the hypothesis that patients who need extended anticoagulant therapy for DVT/PE will have fewer bleeding events on low-dose rivaroxaban or low-dose apixaban than patients on warfarin INR 2-3.

The primary objectives of the COVET study are to determine, in patients at high-risk for recurrent VTE, if apixaban and/or rivaroxaban are superior to warfarin in the reduction of clinically relevant bleeding and the prevention of recurrent VTE. The secondary objective is to compare the rates of clinically relevant bleeding and recurrent VTEs between apixaban and rivaroxaban in this patient population. Eligible patients are consented and randomized to one of three arms: Warfarin target INR 2-3, Rivaroxaban 10 mg daily, or Apixaban 2.5 mg twice daily. Baseline medical history, height and weight, and medications are collected by the study team after consent, and patients have three scheduled phone calls at 1 month, 6 months, and 12 months post-randomization at which time relevant outcome events and medications are assessed. These are performed by a centralized call center coordinated by Duke University (the coordinating site); there are no extra study visits required. Patients will be provided with a study participation journal that they can use to capture event information between scheduled phone calls, however these will only be used as a helpful tool for patients and are neither required nor will be used as source documents.

Some key eligibility criteria include:

- Patients must have had ONE historic episode of lower extremity DVT and/or PE that is not associated with a transient risk factor
- Patients must have completed oral anticoagulant therapy for 3-12 months and have a recommendation to continue indefinitely
- Patients cannot have active cancer
- Patients cannot have another indication for chronic therapeutic-dose

anticoagulation, such as atrial fibrillation
- Patients must be willing to be randomized to any of the three medications for the duration of the study, and must cover any out-of-pocket cost associated with these medications
- The study does provide a $60 co-pay assistance card for patients with commercial insurance, which will be applied after their insurance is applied.

Other details: ClinicalTrials.gov Identifier: NCT03196349; the study sponsor is PCORI (a federal funding agency – Patient-centered Outcome Research Institute).

Questions about the study (including inquiries about becoming a site that enrolls patients) can be addressed to the National PI, **Tom Ortel** at **ortel001@mc.duke.edu**, or to **David Garcia** at **davidg99@uw.edu**. Canadian ACF members with questions should contact **Lana Castellucci** at **lcastellucci@toh.ca**.

Participate Now - AC Forum Survey: Are you Using Andexanet?

Reminder to take a few moments to complete this survey. The Anticoagulation Forum recognizes that many clinicians and hospital administrators have questions relating to practical aspects of andexanet alfa. In response, we have created a brief survey to solicit valuable information from those who are already using it, as well as those who do not have access or have not added it to formulary.

Complete Survey

Roche Diagnostics Recalls CoaguChek XS PT Test Strips Due to Inaccurate INR Test Results

More than 1.1 million devices are subject to this recall. To learn more about the recall and how to receive replacement products visit the CoaguCheck website: **http://www.coaguchek-usa.com/coaguchek_hcp/en_US/home.html**
